The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin

This study is currently recruiting participants.

Verified by Hadassah Medical Organization, May 2008

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00354796

Purpose

We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.

Condition
Acute Coronary Syndrome Venous Thromboembolism Atrial Fibrillation Hypercoagulability

Genetics Home Reference related topics: Brugada syndrome factor V Leiden thrombophilia familial atrial fibrillation short QT syndrome

Drug Information available for: Enoxaparin Sodium

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	500
Study Start Date:	July 2006
Estimated Study Completion Date:	October 2011

Detailed Description:

Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients admitted to tertiary hospital

Criteria

Inclusion Criteria:

treatment with enoxaparin

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00354796

Contacts

Contact: Mordechai Muszkat, MD

00-972-2-6776449

muszkatm@hadassah.org.il

Locations

Israel
Hadassah Medical Organization	Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD 00 972 2 6776095 arik@hadassah.org.il
Contact: hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
Principal Investigator: Mordechai Muszkat, MD

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:

Mordechai Muszkat, MD

Hadassah University Hospital

More Information

Responsible Party:	Hadassah University Hospital ( Mordechai Muszkat )
Study ID Numbers:	enoxap-HMO-CTIL
Study First Received:	July 19, 2006
Last Updated:	May 12, 2008
ClinicalTrials.gov Identifier:	NCT00354796
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:

bleeding
anticoagulation
LMWH
Enoxaparin

Study placed in the following topic categories:

Heart Diseases
Hematologic Diseases
Myocardial Ischemia
Thrombophilia
Vascular Diseases
Ischemia
Venous Thromboembolism
Hemorrhage

Thromboembolism
Thrombosis
Enoxaparin
Embolism and Thrombosis
Embolism
Acute Coronary Syndrome
Atrial Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Fibrin Modulating Agents
Anticoagulants
Disease
Pathologic Processes
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Syndrome
Hematologic Agents
Fibrinolytic Agents
Cardiovascular Diseases
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009